Blätter-Navigation

Of­f­re 86 sur 94 du 06/03/2020, 11:01

logo

Cha­rité - Uni­ver­si­täts­me­di­zin Ber­lin - Moleku­lares Krebsforschung­szen­trum (MKFZ) - Char­ité Cam­pus Virchow-Klinikum

The Char­ité - Uni­ver­si­täts­med­izin Ber­lin is a joint med­ical fac­ulty, which ser­ves both Freie Uni­ver­si­tät Ber­lin and Hum­boldt Uni­ver­si­tät zu Ber­lin. As one of the lar­gest uni­ver­sity hos­pit­als in Europe with an import­ant his­tory, it plays a lead­ing role in rese­arch, teach­ing and clin­ical care. The Char­ité uni­ver­sity hos­pital has also made a name for its­elf as a mod­ern busi­ness with cer­ti­fic­a­tions in the med­ical, clin­ical and man­age­ment fields.

Sci­entific staff (Postdoc)

Work­ing field:

We are inter­ested in genetic pro­grams and defects therein, which impact on tumor devel­op­ment and sens­it­iv­ity to anti­c­an­cer ther­apies, in par­tic­u­lar cel­lu­lar sen­es­cence, apop­tosis and auto­phagy. We util­ize trans­genic mouse lymph­oma (and other can­cer) mod­els with and without defined genetic lesions to dis­sect molecu­lar mech­an­isms and to explore drug respons­ive­ness in vivo by mul­tiple omics tech­niques (gen­om­ics, tran­scrip­tom­ics, pro­teo­m­ics and meta­bolomcs) in a clin­ical trial-like format. This strategy is embed­ded in func­tional in vitro and in vivo invest­ig­a­tions of primary human tumor mater­ial, espe­cially lymph­o­mas, in short-term cul­ture and as patient-derived xeno­grafts.

Your area of respons­ib­il­it­ies:

Can­cer mod­els and mul­tiom­ics ana­lysis

Cur­rently avail­able pos­i­tion is embed­ded in a pro­ject aim­ing to estab­lish innov­at­ive non-animal model sys­tems for can­cer research. Exper­i­ence in mouse mod­els and mul­tiom­ics, par­tic­u­larly single-cell ana­lysis, are not required but would be higly val­ued. Spe­cific exper­i­mental approaches focus on (epi-)genet­ics, sig­nal­ing, meta­bol­ism, stem­ness, plas­ti­city and immun­o­gen­i­city. Our cent­ral aim is to under­stand the role of altered cel­lu­lar states in can­cer bio­logy and clin­ical present­a­tion, and to con­vert molecu­lar vul­ner­ab­il­it­ies iden­ti­fied in these test plat­forms into con­cep­tu­ally novel anti­c­an­cer ther­apies.
For inform­a­tion in greater detail please see, for example, pub­lic­a­tions from our lab such as Mil­an­ovic-M et al., Nature 2018, Yu-Y et al., Can­cer Cell 2018, Jing-D et al., Blood 2017 or Dörr-JR et al., Nature 2013, and recent review art­icles by Mil­an­ovic-M et al. (Trends Cell Biol 2019) or Lee-S and Schmitt-CA (Nat Cell Biol 2019). Our study group is co-affil­i­ated with the Depart­ment of Hem­at­o­logy, Onco­logy and Tumor Immun­o­logy at the Char­ité - Uni­versity Med­ical Cen­ter (Hum­boldt Uni­versity and Free Uni­versity) and the Max-Del­brück-Cen­ter for Molecu­lar Medi­cine (MDC) in Ber­lin.Moreover, we are part­ner in the inter­dis­cip­lin­ary Ger­man Can­cer Con­sor­tium (GCC) for Trans­la­tional Can­cer Research, the Inter­na­tional Gradu­ate Pro­gram “Ber­lin School of Integ­rat­ive Onco­logy (BSIO)” and other con­sor­tia with a focus on com­pu­ta­tional bio­logy. Ber­lin is the place to con­duct innov­at­ive and inter­dis­cip­lin­ary research, provides a very inter­na­tional envir­on­ment and high life qual­ity, and is one of the most vibrant cit­ies in Europe.

Require­ments:

Join our highly motiv­ated team if you are inter­ested in sys­tems medi­cine-driven approaches and novel strategies to dis­sect treat­ment- and out­come-rel­ev­ant sig­nal­ing mod­ules and cell states in can­cer. You hold a Ph.D. or equi­val­ent, and you are famil­iar with all basic tech­niques in molecu­lar bio­logy, bio­chem­istry and his­to­logy (i.e. clon­ing and genetic modi­fic­a­tions like CRISPR, ana­lyses of pro­teins and DNA/RNA, cell cul­ture, and immun­o­his­to­chem­istry). Exper­i­ence with mouse mod­els and com­pu­ta­tional ana­lysis would be highly val­ued. Lab com­mu­nic­a­tion is in Eng­lish.

How to ap­ply:

Please send your CV includ­ing a list of pub­lic­a­tions and two ref­er­ences/let­ters of recom­mend­a­tion to

Prof. Dr. Clem­ens A. Schmitt, M.D.
Char­ité/Cam­pus Virchow/Hem­at­o­logy-Onco­logy, and
Max-Del­brück-Cen­ter for Molecu­lar Medi­cine
Augusten­bur­ger Platz 1
D-13353 Ber­lin
Ger­many

e-mail clemens.schmitt@charite.de

DIE CHAR­ITÉ – UNI­VERSITÄTSMED­IZIN BER­LIN makes its human resources decisions based on suit­ab­il­ity, com­pet­ence and pro­fes­sional per­form­ance. At the same time, it strives to increase the per­cent­age of women in man­age­ment pos­i­tions and takes this into con­sid­er­a­tion where can­did­ates are equally qual­i­fied within the lim­its of what is leg­ally pos­sible. Applic­a­tions from people with a migrant back­ground are also expli­citly wel­come. Severely dis­abled applic­ants are given pref­er­en­tial con­sid­er­a­tion in the case of can­did­ates with equal qual­i­fic­a­tions. An exten­ded cer­ti­fic­ate of con­duct must be sub­mit­ted. Any travel expenses incurred can­not be reim­bursed.

Data pro­tec­tion notice: Char­ité points out that per­sonal data is stored and pro­cessed as part of the applic­a­tion pro­cess in dif­fer­ent areas of Char­ité (e.g. fac­ulty, staff com­mit­tee, human resources depart­ment). Fur­ther­more, the data may be trans­ferred or pro­cessed within the group as well as in loc­a­tions out­side the group (e.g. author­it­ies) to pro­tect legit­im­ate interests. By apply­ing, you agree to our data pro­tec­tion reg­u­la­tions and terms of use, which you can find here:

https://www.charite.de/service/datenschutz/bewerbungsverfahren/